The patent describes the extraction and standardization of stable doses of psychedelic compounds VANCOUVER, BC, April 13, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a patent by the United States Patent and Trademark Office (USPTO) for the…


Previous articleFilament Health Announces Pre-ind Meeting With United States Food And Drug Administration
Next articlePsychedelic Bulletin: Numinus to Enter U.S. Clinics Market; Mydecine Announces Reverse Stock-Split; Are Magic Mushrooms Giving Investors a Bad Trip?